UNASSIGNED: This detailed review summarizes recent developments in the field antiarrhythmic drugs in the field AF.
UNASSIGNED: The current situation is far than optimal. Despite clear unmet needs in drug development in the field of AF treatment, the current development of new drugs is absent. The need for a molecule with absence of cardiac and non-cardiac toxicity in the short and long term is a limitation in the field. Improvement in the understanding of AF genetics, pathophysiology, molecular alterations, big data and artificial intelligence with the objective to provide a personalized AF treatment will be the cornerstone of AF treatment in the coming years.
■这篇详细的综述总结了房颤领域抗心律失常药物的最新进展。
■目前的情况远非最佳。尽管在AF治疗领域的药物开发中存在明显的未满足的需求,目前缺乏新药的开发。对短期和长期不存在心脏和非心脏毒性的分子的需要是本领域的限制。提高对AF遗传学的理解,病理生理学,分子改变,以提供个性化AF治疗为目标的大数据和人工智能将是未来几年AF治疗的基石。